Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush

Key Points

• Wedbush has reaffirmed an "outperform" rating for Perspective Therapeutics (CATX) with a price target of $11.00, suggesting a potential upside of 261.25% from its current price.
• Currently, the consensus rating for CATX is "Buy" with an average price target of $12.70, reflecting positive sentiment among multiple research analysts.
• Despite favorable ratings, CATX shares recently dropped 32.2%, trading at $3.05, following a significant fluctuation in volume.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "outperform" rating reissued by research analysts at Wedbush in a report released on Monday,RTT News reports. They presently have a $11.00 price objective on the stock. Wedbush's price objective would indicate a potential upside of 261.25% from the stock's current price.

A number of other research analysts also recently weighed in on the company. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 3rd. B. Riley reaffirmed a "buy" rating and issued a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Finally, BTIG Research began coverage on Perspective Therapeutics in a research report on Friday, October 10th. They set a "buy" rating and a $14.00 price target on the stock. Four research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $12.70.

Perspective Therapeutics Trading Down 32.2%

Shares of CATX traded down $1.45 during midday trading on Monday, reaching $3.05. The stock had a trading volume of 2,649,410 shares, compared to its average volume of 951,953. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $12.90. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01. The firm's 50 day moving average price is $3.63 and its 200-day moving average price is $3.24.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ground Swell Capital LLC bought a new position in Perspective Therapeutics during the second quarter worth about $56,000. Los Angeles Capital Management LLC acquired a new position in Perspective Therapeutics during the second quarter valued at approximately $61,000. MetLife Investment Management LLC raised its position in Perspective Therapeutics by 40.9% during the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company's stock valued at $67,000 after purchasing an additional 9,082 shares in the last quarter. Trueblood Wealth Management LLC raised its position in Perspective Therapeutics by 210.6% during the second quarter. Trueblood Wealth Management LLC now owns 69,061 shares of the company's stock valued at $238,000 after purchasing an additional 46,825 shares in the last quarter. Finally, Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 4.4% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company's stock worth $323,000 after buying an additional 4,000 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.